HBM Holdings-B (02142) surged nearly 5%, reaching HK$13.62 by the time of writing, with a trading volume of HK$15.42 million. The uptick follows an announcement on November 24, where the company disclosed that its indirect wholly-owned subsidiary, HBM (Shanghai), has amended and expanded its collaboration agreement with AstraZeneca PLC (AZN). The revised agreement broadens the scope of their partnership to jointly discover and develop next-generation biologic therapies, including antibody-drug conjugates (ADCs) and T-cell engagers. The financial terms remain consistent with the framework established in the original agreement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments